BridgeBio Pharma has raised $135m to support the continued development of its genetic disease drug pipeline. The company operates a “hub and spoke” structure, whereby it sources genetic disease treatments and creates subsidiaries to develop them, providing access to centralised resources and a research and development platform. It has more than 12 assets in preclinical and clinical development. Its lead programme, from subsidiary Eidos Therapeutics, which targets ATTR polyneuropathy and cardiomyopathy, is currently in phase 3.
BridgeBio Pharma has raised $299.2m to support the continued development of its genetic disease drug pipeline. The company operates a “hub and spoke” structure, whereby it sources genetic disease treatments and creates subsidiaries to develop them, providing access to centralised resources and a research and development platform. It has more than 12 assets in preclinical and clinical development. Its lead programme, from subsidiary Eidos Therapeutics, which targets ATTR polyneuropathy and cardiomyopathy, is currently in phase 3.